Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.59 |
| ▸ | MAPT | P10636 | 2/20 | 0.59 |
| ▸ | DPP4 | P27487 | 1/20 | 0.52 |
| ▸ | TP53 | P04637 | 1/20 | 0.47 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.43 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.43 |
| ▸ | MGLL | Q99685 | 1/20 | 0.43 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.41 |
| ▸ | NR2F2 | P24468 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20129614 | 0.86 | TP53 (0.50) | ALDH1A1LMNAMAPTDPP4TP53 | |
| SCHEMBL14103789 | 0.86 | VEGFA (0.53) | TP53HDAC1HDAC6MGLLSMN1; SMN2 | |
| SCHEMBL22532823 | 0.86 | TP53 (0.50) | ALDH1A1LMNAMAPTDPP4TP53 | |
| SCHEMBL4158417 | 0.85 | DPP4 (0.49) | ALDH1A1DPP4TP53HDAC1HDAC6 | |
| SCHEMBL1876106 | 0.85 | TP53 (0.49) | ALDH1A1LMNAMAPTTP53HDAC1 | |
| SCHEMBL5283535 | 0.85 | TP53 (0.49) | ALDH1A1LMNAMAPTDPP4TP53 | |
| SCHEMBL4297578 | 0.85 | NR1H2 (0.50) | ALDH1A1MAPTDPP4TP53HDAC1 | |
| SCHEMBL1049753 | 0.84 | HDAC1 (0.50) | DPP4TP53HDAC1HDAC6MAPK1 | |
| SCHEMBL2262766 | 0.84 | CYP3A4 (0.52) | ALDH1A1LMNAMAPTDPP4TP53 | |
| SCHEMBL1081669 | 0.84 | HDAC1 (0.50) | LMNAMAPTTP53HDAC1HDAC6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. | 2023-05-04 | — | — | US | disclosed |
| CN-115515934-A | NAMPT modulators | 赛特凯恩蒂克公司 | 2022-12-23 | — | — | CN | disclosed |
| EP-4100393-A1 | NAMPT MODULATORS | Cytokinetics, Inc. (US) | 2022-12-14 | — | — | EP | disclosed |
| WO-2021159015-A1 | NAMPT MODULATORS | CYTOKINETICS, INC. (US) | 2021-08-12 | — | — | WO | disclosed |
| US-6680312-B2 | FOR THERAPY OF CARDIAC INFARCTION, CEREBRAL THROMBOSIS; INHIBIT ACTIVATED COAGULATION FACTOR X (FXA) TO SHOW ANTI-COAGULANT ACTIVITY | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2004-01-20 | — | — | US | disclosed |
| US-20020193382-A1 | Sulfonamide derivatives, their production and use | TAKEDA PHARMACEUTICAL COMPANY, LIMITED (JP) | 2002-12-19 | — | — | US | disclosed |
| US-6403595-B1 | ANTICOAGULANTS | TAKEDA CHEMICAL INDUSTRIES, LTD. (JP) | 2002-06-11 | — | — | US | disclosed |
| EP-1054005-A1 | SULFONAMIDE DERIVATIVES, PROCESS FOR PRODUCING THE SAME AND UTILIZATION THEREOF | Takeda Chemical Industries, Ltd. (JP) | 2000-11-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230133132-A1 | NAMPT MODULATORS | NAMPT, MC4R, SIRT1 | ALDH1A1 2019/4885LMNA 2810/4885MAPT 718/4885 |
| US-20020193382-A1 | Sulfonamide derivatives, their production and use | F12, F11, F2 | ALDH1A1 2304/4885LMNA 832/4885MAPT 4851/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.